RXRX AI Price Prediction

The company is currently unprofitable, as indicated by its negative EPS and PE ratio. This suggests Recursion Pharmaceuticals is still in an investment and development phase, relying on external capital rather than internally generated cash. Until there is a clear path to profitability or accelerating revenue growth, the financial profile remains high-risk.

• Negative EPS of -1.16 indicates ongoing losses and lack of current earnings power.
• A PE ratio of -2.72 confirms that the stock is not generating positive earnings, typical of early-stage or R&D-heavy biotech/AI-drug discovery firms.
• Without evidence of improving margins or approaching breakeven, the current financials point to continued dilution or funding needs, which is a headwind for equity holders.

Despite a 7.5% gain over the last month, the stock trades at $3.15, well below its 200-day moving average of $4.18, signaling a broader downtrend. The recent bounce appears more like a short-term relief move within a longer-term bearish pattern. Until price can reclaim and hold above the 200-day moving average, the technical setup remains weak.

• Current price of $3.15 is materially below the 200-day moving average of $4.18, a classic sign of a prevailing downtrend.
• The 7.5% one-month increase is positive but modest relative to the longer-term decline implied by the 200-day average, suggesting only a partial recovery.
• Given the negative earnings backdrop, the technicals do not yet show a confirmed trend reversal; the stock remains vulnerable to further downside if sentiment or funding conditions worsen.

Overall, the setup for Recursion Pharmaceuticals leans bearish. The company remains unprofitable, and the stock trades below its 200-day moving average despite a recent short-term bounce. While alternative data shows modest engagement and operational stability, it is not strong enough to offset the weak financial and technical profile.

• Unprofitable operations and negative earnings, combined with a stock price below the 200-day moving average, point to a risk-heavy, structurally weak position.
• Alternative data signals are mildly constructive but incremental, suggesting interest and stability rather than a clear inflection that would justify a more bullish stance at this time.